The company’s HIV-focused unit ViiV Healthcare’s cabotegravir long-acting injectable and tablets received the authorization.
Tag Archive for: cabotegravir
GSK said the EMA’s Committee for Medicinal Products for Human Use’s (CHMP) positive opinion was based on results from studies in which the medicine, given as few as six times per year, demonstrated superior efficacy to a daily oral PrEP option in reducing the risk of HIV.
The company has signed deals with three companies allowing them to make inexpensive generic versions of its long-acting HIV preventive medicine for use in lower-income countries, where the majority of new HIV cases occur.
The treatment, developed by British drugmaker GlaxoSmithKline, is the first non-pill option against HIV, and studies have shown it even outperforms the efficacy of oral pills.
British drugmaker GSK has struck a deal to allow low-cost generic versions of its long-acting HIV preventive medicine to be used in the developing world, including sub-Saharan Africa where the virus remains a leading cause of death.
